AngioDynamics Inc ANGO.OQ ANGO.O is expected to show a rise in quarterly revenue when it reports results on October 2 for the period ending August 31 2025
The Latham New York-based company is expected to report a 7.8% increase in revenue to $72.725 million from $67.49 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for AngioDynamics Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for AngioDynamics Inc is $16.50, about 34.9% above its last closing price of $10.74
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
May. 31 2025 | -0.13 | -0.12 | -0.03 | Beat | 75 |
Feb. 28 2025 | -0.14 | -0.13 | 0.03 | Beat | 123.1 |
Nov. 30 2024 | -0.10 | -0.11 | -0.04 | Beat | 63.6 |
Aug. 31 2024 | -0.15 | -0.15 | -0.11 | Beat | 25 |
May. 31 2024 | -0.16 | -0.17 | -0.06 | Beat | 64 |
Feb. 29 2024 | -0.13 | -0.14 | -0.16 | Missed | -18.3 |
Nov. 30 2023 | -0.09 | -0.07 | -0.05 | Beat | 33.3 |
Aug. 31 2023 | -0.13 | -0.13 | -0.12 | Beat | 7.7 |
This summary was machine generated September 30 at 12:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)